Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2646172 | 0.81 | DGAT1 (0.43) | DGAT1PDE10AKLKB1 | |
| SCHEMBL15315929 | 0.80 | DGAT1 (0.39) | DGAT1PDE10AKLKB1 | |
| SCHEMBL7495729 | 0.78 | DGAT1 (0.38) | DGAT1PDE10AKLKB1 | |
| SCHEMBL21465294 | 0.77 | DGAT1 (0.43) | DGAT1PDE10AKLKB1 | |
| SCHEMBL25129888 | 0.77 | PDE10A (0.35) | DGAT1PDE10AKLKB1 | |
| SCHEMBL2983095 | 0.76 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL19404674 | 0.75 | DGAT1 (0.47) | DGAT1PDE10AKLKB1 | |
| SCHEMBL29403847 | 0.75 | DGAT1 (0.41) | DGAT1PDE10AKLKB1 | |
| SCHEMBL26103662 | 0.75 | DGAT1 (0.41) | DGAT1PDE10AKLKB1 | |
| SCHEMBL23123392 | 0.74 | DGAT1 (0.43) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675606-B2 | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors | SANOFI (FR) | 2017-06-13 | — | — | US | disclosed |
| US-20150328205-A1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | SANOFI (FR) | 2015-11-19 | — | — | US | disclosed |
| US-9126972-B2 | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors | SANOFI (FR) | 2015-09-08 | — | — | US | disclosed |
| EP-2709996-B1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | SANOFI SA (FR) | 2015-06-24 | — | — | EP | disclosed |
| EP-2709996-A1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | SANOFI (FR) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012159959-A1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | SANOFI (FR) | 2012-11-29 | — | — | WO | disclosed |
| EP-2524915-A1 | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328205-A1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | KDR, FLT4, FLT1 | DGAT1 4726/4885PDE10A 2200/4885KLKB1 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.